›
Medicinal Products
The Minister said the HSE has sole responsibility for medicine pricing and reimbursement decisions. Acarizax’s full health technology assessment is ongoing, and its application remains under consideration; the HSE gave no completion timeline or indication of the outcome.
1708. Deputy Michael Collins asked the Minister for Health to provide an update on the status of the full health technology assessment (HTA ID: 25069) being undertaken by the National Centre for Pharmacoeconomics in respect of house dust mite allergen extract (Acarizax®) for patients aged 5 to 65 years; the current timeline for completion of the assessment and submission of recommendations to the HSE; the stage reached in reimbursement and pricing discussions relating to the medicine; the timeline within which the HSE Corporate Pharmaceutical Unit expects to conclude its consideration of the product for reimbursement under the drugs payment scheme. [75439/26]
Comment on this
1741. Deputy Ryan O'Meara asked the Minister for Health for an update on the pricing and reimbursement application for a drug (details supplied); the current stage of this application; and when it is expected a decision will be made on this application. [75575/26]
Comment on this
1743. Deputy Ryan O'Meara asked the Minister for Health if her Department and HSE will make efforts to progress and expedite ongoing pricing and reimbursement applications, including a drug (details supplied), to ensure affordable access to patients as soon as possible. [75579/26]
Comment on this
1745. Deputy Ryan O'Meara asked the Minister for Health why a drug (details supplied) is not covered under the drugs payment scheme; and the support that is available to households facing the cost of this drug with no DPS support. [75577/26]
Comment on this
I propose to take Questions Nos. 1708, 1741, 1743 and 1745 together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013 the HSE has sole statutory responsibility for decisions on pricing and reimbursement of medicines. The HSE must assess applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to people living in Ireland.
HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds. There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed.
In line with the 2013 Act and the national framework agreed with industry, a company must submit an application to the HSE to have a new medicine added to the reimbursement list and continue to engage at all stages of the process with the HSE to progress applications. Reimbursement is for licenced indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health Products Regulatory Authority (HPRA).
Once the process has begun, applicants must continue to engage throughout the process to ensure that the necessary evidence is available for the HSE to carry out its statutory role as a decision-maker with respect to the reimbursement of new medicines, in accordance with the Act. The Act specifies nine criteria which must be considered. These include the health needs of the public and the clinical need for the medicine. All these factors, taken together, allow the HSE to make an informed decision on new medicines.
In terms of the specific details of the application for pricing and reimbursement of house dust mite extract (Acarizax®):
The HSE received a complete application for pricing and reimbursement of house dust mite extract (Acarizax®) on the 10th December 2025 from ALK-Abello (the applicant) indicated in patients (5-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.
The HSE commissioned a full Health Technology Assessment (HTA) on 28th January 2026, which is ongoing.
Further information on the progress of house dust mite extract (Acarizax®) through the HSE assessment and approval processes is available via the Pricing and Reimbursement Application tracker available at [www.hse.ie/eng/about/who/cpu/] . HSE application ID HSE100082 has been assigned to this application. Information in relation to the pharmacoeconomic assessment being conducted by the National Centre for Pharmacoeconomics can be found at House Dust Mite Extract (Acarizax ®) for Allergic Rhinitis (5-65 year olds) HTA ID: 25069 | National Centre for Pharmacoeconomics (/www.ncpe.ie/house-dust-mite-extract-acarizax-for-allergic-rhinitis-5-65-year-olds-hta-id-25069/).
The application remains under consideration with the HSE. The HSE cannot make any comment on possible outcomes from the ongoing process.